Focus Area: Immuno-Materials
135 Results for 'Immuno-Materials'
- Technologies (16)
- Collaborations (1)
- Team (0)
- News (96)
- Pages (0)
- Multimedia (22)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 16
-
TIB: Tolerance Inducing Biomaterials for Regulatory T Cells
Easily injectable biomaterial technology to induce and localize regulatory T cells to specific tissues and sustain their pro-regenerative activities in tissue regeneration with a focus on musculoskeletal diseases and injuries. -
Injectable Hydrogel Adhesive for Improved Muscle Regeneration
A super-strong, stretchy, and self-healing biomaterial that adheres to muscles and helps them heal faster after injury. -
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
Tunable ECMs for More Effective T cell Therapies
Tunable hydrogels that enhance the efficacies of adoptively transferred immune cells during their manufacturing by mimicking target tissue biomechanics. -
Soft hydrogel electrodes for better, safer implants
Soft, conductive hydrogels match the physical properties of the human brain, enabling the creation of electrodes and implantable devices that can improve brain-machine interfaces while reducing the risk of injury. -
FeCILL: Targeted Treatment for Severe Fungal Infections
FeCILL is novel delivery vehicle for antifungal drugs that targets them right to the infection site and reduces harmful side effects in patients with severe fungal infections.
Collaborations 1
i3 Center: Biomaterials to Create T Cell ImmunityNews 96
Multimedia 22
-
Video/Animation20-ish Questions with David J. Mooney20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows David J. Mooney, a Founding Core Faculty member and Lead of the Immuno-Materials platform at the Wyss Institute. He is also the Robert P. Pinkas Family Professor of... -
Video/AnimationDavid Mooney on the Mission to Save Lives Through Cancer ResearchDavid Mooney, Core Faculty member of the Wyss Institute and Robert Pinkas Family Professor of Bioengineering in the Harvard School of Engineering and Applied Sciences, discusses training immune cells to recognize and destroy cancer mutations. While current immunotherapies create nearly miraculous cures for some patients, they only work for certain cancers and a fraction of... -
Video/Animation20-ish Questions with Samir Mitragotri20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows Samir Mitragotri, a Core Faculty member of the Wyss Institute as well as a Professor of Bioengineering and Biologically Inspired Engineering at the Harvard John A. Paulson School... -
Video/AnimationHow can we train the immune system to fight cancer?The implantable cancer vaccine is a biomaterial that recruits and reprograms a patient’s own immune cells on-site to kill cancer cells. This revolutionary immuno-material technology was tested in a Phase I clinical trial with promising results and is currently licensed by Novartis as an immunotherapy to treat specific tumor types. Credit: Wyss Institute at Harvard... -
Video/AnimationFeCILL: Reimagining How We Treat the Sickest PatientsOpportunistic fungal infections usually only affect patients whose immune systems are compromised, but when they do, they are often deadly – the mortality rate for these infections can be as high as 25%. Existing antifungal treatments have high levels of toxicity, and can harm the patient more than they help. Researchers at the Wyss Institute... -
Video/AnimationMetabolic T cell Labeling: simple and effective enhancement of therapeutic T cells with immune-stimulating cytokinesThis animation shows how the surface of patient-derived T cells is metabolically labeled with azido-sugar molecules that then can be used to attach immune-enhancing cytokines with the help of click chemistry. The approach could help expand adoptive T cell therapies to treatment of solid tumors. Credit: Wyss Institute at Harvard University